SCHEMBL1490425

SCHEMBL1490425

COC(=O)c1c(NC(=O)OCc2ccccc2)csc1-c1ccc(Br)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
HDAC3 O15379 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
HTT P42858 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PTPN1 P18031 1/20 0.43
PRKCZ Q05513 2/20 0.43
TRPV1 Q8NER1 1/20 0.41
MGLL Q99685 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TACR3 P29371 1/20 0.40
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490684 0.90 NPC1 (0.52) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL12756642 0.90 HDAC3 (0.50) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL1490651 0.89 NPC1 (0.48) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL1490594 0.89 MGLL (0.52) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL1490577 0.88 HDAC3 (0.45) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL3555247 0.82 NPC1 (0.58) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL1490217 0.79 NPC1 (0.52) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL1491014 0.79 HDAC3 (0.50) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL1490720 0.77 NPC1 (0.50) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL1490620 0.77 RAB9A (0.47) RAB9ANPC1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 US disclosed
US-8618307-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2013-12-31 US disclosed
EP-2477982-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2012-07-25 EP disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 WO disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 RAB9A 1174/4885NPC1 262/4885HDAC3 1653/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 RAB9A 1174/4885NPC1 262/4885HDAC3 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.